-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $120

Benzinga·06/24/2025 16:33:30
Listen to the news
HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $6.5 to $120.